Bulk Inquiry
ABBV-744
- Soluble in DMSO
- MF: C28H30FN3O4
- MW: 491.55
Description
ABBV-744 is an orally available first-in-class highly BDII (Bromodomain II)-selective (>100 X selectivity over BDI) BET bromodomain inhibitor, currently is being investigated to treat AML and metastic castration-resistant prostate cancer.
More Information
| Parent CAS No. | 2138861-99-9 |
|---|---|
| Chemical Name | N-Ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide |
| extra_info | Sold in collaboration with Chemietek |
| MFCD | N.A |
| Short Description | BDII selective BET bromodomain inhibitor |
References
- GS Sheppard, et al, Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL
- EJ Faivre et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020 Feb;578(7794):306-310.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1887 | PFI-1 |
From $82.50 |
| 1989 | (+)-JQ1 |
From $66.00 |
| 2245 | RVX 208 |
From $71.50 |
| 2530 | OTX 015 |
From $121.00 |
| 2594 | CPI 0610 |
From Inquiry |
| 2776 | CD161 |
From $154.00 |
| 3037 | BET BRD4 inhibitor compound II-25 |
From $181.50 |
| 3324 | Thalidomide |
From $55.00 |
| 3329 | ODM-207 |
From $154.00 |
| 3696 | ABBV-075 |
From $121.00 |
| 3716 | BMS-986158 |
From Inquiry |
| 3860 | I-BET726 |
From Inquiry |
| 3873 | (-)-JQ-1 |
From $132.00 |
| 3922 | dBET1 |
From Inquiry |
| 3933 | CCS-1477 |
From Inquiry |
| 3944 | ARV-825 |
From Inquiry |
| 4134 | I-BET762 |
From Inquiry |
| 4135 | I-BET151 |
From Inquiry |
